Canaccord Genuity Sticks to Their Hold Rating for Angiodynamics

By Jason Carr

In a report released today, Jason Mills from Canaccord Genuity reiterated a Hold rating on Angiodynamics (NASDAQ: ANGO), with a price target of $16.50. The company’s shares opened today at $15.08.

According to, Mills is a 5-star analyst with an average return of 11.7% and a 66.5% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.

Angiodynamics has an analyst consensus of Moderate Buy, with a price target consensus of $19.17.

The company has a one year high of $18.18 and a one year low of $11.92. Currently, Angiodynamics has an average volume of 288K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AngioDynamics, Inc. engages in the business of medical devices. Its activities include design, manufactures, and sale of medical, surgical and diagnostic devices. The company focuses on devices in the field of vascular access, peripheral vascular, oncology, and surgery. AngioDynamics was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.